{"id":"sandimmune-injection","safety":{"commonSideEffects":[{"rate":"25-50","effect":"Nephrotoxicity/renal dysfunction"},{"rate":"25-50","effect":"Hypertension"},{"rate":"10-25","effect":"Tremor"},{"rate":"10-30","effect":"Gingival hyperplasia"},{"rate":"10-25","effect":"Hirsutism"},{"rate":"10-20","effect":"Headache"},{"rate":"20-40","effect":"Infection"},{"rate":"10-20","effect":"Hyperkalemia"}]},"_chembl":{"chemblId":"CHEMBL2108760","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cyclosporine binds to cyclophilin and forms a complex that inhibits calcineurin phosphatase, blocking the dephosphorylation of nuclear factor of activated T cells (NFAT). This prevents T-cell activation, IL-2 production, and proliferation of T lymphocytes. The drug is used primarily to prevent organ transplant rejection and treat autoimmune conditions by suppressing cellular immunity.","oneSentence":"Sandimmune (cyclosporine) suppresses T-cell activation and proliferation by inhibiting calcineurin, thereby reducing immune-mediated rejection and inflammatory responses.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:06:50.251Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of organ rejection in transplant recipients (kidney, heart, liver, pancreas)"},{"name":"Severe active rheumatoid arthritis"},{"name":"Severe psoriasis"},{"name":"Nephrotic syndrome"}]},"trialDetails":[{"nctId":"NCT06790095","phase":"PHASE2","title":"TRACK-TBI Precision Medicine Part 3 - Option II","status":"ENROLLING_BY_INVITATION","sponsor":"University of California, San Francisco","startDate":"2026-02","conditions":"Traumatic Brain Injury","enrollment":26},{"nctId":"NCT07021495","phase":"","title":"SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2025-07-29","conditions":"Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS), Psoriasis (PsO)","enrollment":840},{"nctId":"NCT05323617","phase":"PHASE2","title":"Efficacy of Romiplostim in Treatment of SAA in Adults Previously Untreated With or Refractory to Immunosuppressive Therapy","status":"WITHDRAWN","sponsor":"Amgen","startDate":"2023-08-31","conditions":"Severe Aplastic Anemia (SAA)","enrollment":""},{"nctId":"NCT05293509","phase":"PHASE2","title":"Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-03-02","conditions":"Stem Cell Transplantation","enrollment":""},{"nctId":"NCT02328755","phase":"PHASE1, PHASE2","title":"Peginterferon Alfa-2a to Enhance Anti-leukemic Responses After Allogeneic Transplantation in Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2015-01","conditions":"Acute Myeloid Leukemia","enrollment":37},{"nctId":"NCT02755649","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Dupilumab in Participants With Severe Atopic Dermatitis (AD) That Are Not Controlled With Oral Cyclosporine A (CSA) or for Those Who Cannot Take Oral CSA Because it is Not Medically Advisable","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2016-01-31","conditions":"Atopic Dermatitis","enrollment":325},{"nctId":"NCT02167958","phase":"PHASE1","title":"Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source","status":"COMPLETED","sponsor":"Rafic Farah, MD","startDate":"2015-02-11","conditions":"Leukemia, MDS, Myelofibrosis","enrollment":28},{"nctId":"NCT01843348","phase":"PHASE3","title":"12 Month Athena Study: Everolimus vs. Standard Regimen in de Novo Kidney Transplant Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-12-27","conditions":"Kidney Transplantation, Renal Transplantation","enrollment":612},{"nctId":"NCT00514514","phase":"PHASE3","title":"Study Investigating a Standard Regimen in de Novo Kidney Transplant Patients Versus a Calcineurin Inhibitor (CNI)-Free Regimen and a CNI-low Dose Regimen","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2007-07","conditions":"Kidney Transplantation","enrollment":802},{"nctId":"NCT02397213","phase":"PHASE2","title":"Ciclosporin to Protect Renal Function In Cardiac Surgery","status":"COMPLETED","sponsor":"Region Skane","startDate":"2015-04","conditions":"Acute Kidney Injury","enrollment":155},{"nctId":"NCT01901471","phase":"PHASE2","title":"Cyclosporine in Acute Myocardial Infarction Complicated by Cardiogenic Shock","status":"WITHDRAWN","sponsor":"Hospices Civils de Lyon","startDate":"2015-09","conditions":"Acute Myocardial Infarction","enrollment":""},{"nctId":"NCT01868360","phase":"PHASE1","title":"Using Aflibercept Injection to Treat Blood Vessel Growth Over the Cornea","status":"TERMINATED","sponsor":"Balamurali Ambati","startDate":"2013-06","conditions":"Corneal Neovascularization","enrollment":2},{"nctId":"NCT01467505","phase":"PHASE2","title":"An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant Patients","status":"TERMINATED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2012-02","conditions":"Hepatitis C","enrollment":61},{"nctId":"NCT01650662","phase":"PHASE3","title":"CYCLosporinE A in Reperfused Acute Myocardial Infarction","status":"COMPLETED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2012-01","conditions":"Acute Myocardial Infarction","enrollment":410},{"nctId":"NCT01817322","phase":"PHASE4","title":"Kidney Graft Function Under the Immunosuppression Strategies","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2011-06","conditions":"Chronic Renal Disease","enrollment":140},{"nctId":"NCT01002859","phase":"PHASE2","title":"Effect of Preliminary Administration of Cyclosporine (Sandimmun ®) on Different Markers of Cardiac Ischaemia Induced by Cardiopulmonary Bypass","status":"TERMINATED","sponsor":"University Hospital, Grenoble","startDate":"2009-04","conditions":"Coronary Artery Bypass Surgery, Cardiopulmonary Bypass","enrollment":50},{"nctId":"NCT01692834","phase":"PHASE1","title":"A Study to Compare the Bioavailability and Pharmacokinetics of Cyclosporine After Intravenous Administration of NEUROSTAT®, a CREMOPHOR® EL-free Lipid Emulsion, and SANDIMMUNE® Injection (a Suspension of Cyclosporine in CREMOPHOR® EL) in Healthy Volunteers","status":"COMPLETED","sponsor":"NeuroVive Pharmaceutical AB","startDate":"2009-06","conditions":"Healthy","enrollment":65},{"nctId":"NCT01596062","phase":"PHASE2","title":"Pharmacodynamics, Efficacy and Safety of Basiliximab 40 or 80 mg in Combination With Ciclosporine Microemulsion or Everolimus, in Adult Low Risk de Novo Renal Transplant Recipients (IDEALE Study)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-03","conditions":"Renal Transplantation","enrollment":16},{"nctId":"NCT00891306","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Human Lipoprotein Lipase (LPL)[S447X] Expressed by an Adeno-Associated Viral Vector in LPL-deficient Subjects","status":"COMPLETED","sponsor":"Amsterdam Molecular Therapeutics","startDate":"2009-02","conditions":"Familial Lipoprotein Lipase Deficiency","enrollment":5},{"nctId":"NCT00149890","phase":"PHASE3","title":"Efficacy and Safety of Basiliximab, Cyclosporine/Cyclosporine Microemulsion, and Steroids in Pediatric de Novo Liver Transplant Recipients Avoiding Intraoperative Steroids","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-03","conditions":"Liver Transplantation, Infection","enrollment":77}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Sandimmune® Injection","genericName":"Sandimmune® Injection","companyName":"NeuroVive Pharmaceutical AB","companyId":"neurovive-pharmaceutical-ab","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sandimmune (cyclosporine) suppresses T-cell activation and proliferation by inhibiting calcineurin, thereby reducing immune-mediated rejection and inflammatory responses. Used for Prevention of organ rejection in transplant recipients (kidney, heart, liver, pancreas), Severe active rheumatoid arthritis, Severe psoriasis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}